In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin
about
sameAs
Antipneumocystis activity of water-soluble lipopeptide L-693,989 in ratsNew semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the ratIn vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosisAntifungal peptides: novel therapeutic compounds against emerging pathogensTreatment of murine disseminated candidiasis with L-743,872In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)MUC7 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal actionStructural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide.Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.Properties of various Rho1 mutant alleles of Cryptococcus neoformans.Total Synthesis of (+)-Papulacandin DApplication of caspofungin in China compared with amphotericin B and fluconazole.Natural products: a continuing source of novel drug leadsPreliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.Antifungal prophylaxis during neutropenia and immunodeficiencyCharacterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesisDiscovery and development of first in class antifungal caspofungin (CANCIDAS®)--a case study.The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies.A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase.Key issues concerning fungistatic versus fungicidal drugs.Differential activities of three families of specific beta(1,3)glucan synthase inhibitors in wild-type and resistant strains of fission yeastThe contribution of mechanistic understanding to phenotypic screening for first-in-class medicines.Antimicrobial activity of ergokonin A from Trichoderma longibrachiatum.
P2860
Q28316967-F1FCCE54-E05B-47DA-BA78-0BDCF89DEC67Q28367755-6640ED30-65E6-4032-B7ED-F5969185C631Q28367886-91A1A6C1-2A23-488A-BD63-9966670CB6B6Q28367890-7F3838B4-EA67-4FD8-91E4-B5DE79D371B3Q28369443-2DBD2000-22BF-42A7-9CA6-89364959B11FQ28379078-1F59FB34-2BC1-4C0C-97CD-FBC4A8B0E4D4Q28379217-E88697A0-18C3-43F0-AFAC-9373052917C5Q29871517-988CF8D4-D382-4DEC-9547-77D106573CA6Q30687516-70165E7C-18AA-46EE-83A5-91625D435593Q33754208-75E23534-1C25-4144-8E75-E8380793D742Q33791723-35A57FEB-00A6-43AE-85A9-4A6D4BC55565Q34055093-0235212B-587D-41C7-9E70-99622EF72A0CQ34182814-DF32187E-9224-41E3-9258-62B2024EC356Q34328933-A82FB160-7199-4D5F-8E12-B08864BDEB43Q35138759-21022616-7B7F-466C-A8CF-3E1FDDDDB819Q35138937-FD88CF49-2E1C-4066-AD8A-9EA0AB1F3034Q35374928-B5C364E5-2BE7-493E-84A0-3CC14DC4BEC1Q35512289-3DD9F30F-8BD7-42EB-B9C2-218BF61C0C2FQ35823016-260D76B6-84F3-4CD5-AC1D-1E9B39C3E95FQ38165714-8FB33DC0-52E1-4760-B6E8-1FE3296BE341Q38835045-6BD473E4-A6AF-4117-A45F-7A60F471D10EQ39493735-2D7F4C47-C95F-4AA5-90A2-C991C3990905Q39897971-617A302E-5691-455A-B163-34FCE11DAB28Q41377981-967CDC30-30BF-402C-9546-DBA93EE347B7Q42584992-A0E9D077-6A3A-4032-B054-B8BB74C10569Q44143302-3306496B-DFED-407B-9891-4F3A9885B5F2Q48736767-9BB8DE75-045C-4CC7-BC01-5DAD21BDA198
P2860
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
In vitro antifungal activities ...... and L-687,781, a papulacandin
@ast
In vitro antifungal activities ...... and L-687,781, a papulacandin
@en
In vitro antifungal activities ...... and L-687,781, a papulacandin
@nl
type
label
In vitro antifungal activities ...... and L-687,781, a papulacandin
@ast
In vitro antifungal activities ...... and L-687,781, a papulacandin
@en
In vitro antifungal activities ...... and L-687,781, a papulacandin
@nl
prefLabel
In vitro antifungal activities ...... and L-687,781, a papulacandin
@ast
In vitro antifungal activities ...... and L-687,781, a papulacandin
@en
In vitro antifungal activities ...... and L-687,781, a papulacandin
@nl
P2093
P2860
P356
P1476
In vitro antifungal activities ...... and L-687,781, a papulacandin
@en
P2093
F Vanmiddlesworth
J Balkovec
K Bartizal
K Nollstadt
R Schwartz
P2860
P304
P356
10.1128/AAC.36.8.1648
P407
P577
1992-08-01T00:00:00Z